---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-002070"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:16:25.943979+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals enrolls first patient in expanded access study of tafenoquine for persistent babesiosis

## Summary
- First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.
- Prior case series in Clinical Infectious Diseases reported 80% cure rate with tafenoquine plus SOC in five high-risk patients.
- Company estimates cumulative U.S. accessible market for ARAKODA (tafenoquine) in babesiosis may exceed 400,000 patients through Dec 2035.
- Tafenoquine is FDA-approved for malaria prophylaxis (ARAKODA) but not proven effective or approved for babesiosis.

## SEC filing metadata
- accession: 0001213900-25-002070
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/0001213900-25-002070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/ea0227197-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-002070
- JSON: https://secwatch.observer/filing/0001213900-25-002070.json
- Plain text: https://secwatch.observer/filing/0001213900-25-002070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.